HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Malek G. Massad Patrick M. McCarthy Nicholas G. Smedira Jose Navia James B. Young Robert W. Stewart Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Massad, M. G. Articles by Stewart, R. W. Search for Related Content PubMed PubMed Citation Articles by Massad, M. G. Articles by Stewart, R. W.

J Thorac Cardiovasc Surg 1996;112:1275-1283
© 1996 Mosby, Inc.

CARDIAC AND PULMONARY REPLACEMENT

DOES SUCCESSFUL BRIDGING WITH THE IMPLANTABLE LEFT VENTRICULAR ASSIST DEVICE AFFECT CARDIAC TRANSPLANTATION OUTCOME?

Received for publication May 6, 1996 Revisions requested June 18, 1996; revisions received July 22, 1996 Accepted for publication July 26, 1996. Address for reprints: Patrick M. McCarthy, MD, Department of Thoracic and Cardiovascular Surgery, F25, Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH 44195.

Abstract

Objectives: We sought to determine whether cardiac transplant recipients who required a bridge to transplantation with an implantable left ventricular assist device had a different outcome than patients who underwent transplantation without such a bridge.

Methods: A retrospective study of 256 cardiac transplants from 1992 to 1996 included 53 patients who received the HeartMate left ventricular assist device and 203 patients who had no left ventricular assist device support.

Results: Left ventricular assist device transplants increased from 8% of all transplants in 1992 (n= 63) to 32% in 1995 (n= 65) and 43% in 1996 (n= 14 year to date). Patients with and without left ventricular assist device had similar age and sex distributions. Left ventricular assist device recipients were larger (body surface area 1.96 vs 1.86 m², p = 0.004). They were more likely to have ischemic cardiomyopathy (70% vs 45%, p= 0.001) and type O blood group (51% vs 34%, p= 0.06). All patients with left ventricular assist device and 42% of those without had undergone previous cardiac operations by the time of transplantation (mean number per patient 1.5 vs 0.3, p< 0.001). More patients in the left ventricular assist device group had anti-HLA antibodies before transplantation (T-cell panel reactive antibody level >10% in 66% of left ventricular assist device group vs 15% of control group, p< 0.0001). Waiting time was longer for the left ventricular assist device than for patients in status I without a left ventricular assist device (median 88 vs 37 days, p= 0.002). There was no difference in length of posttransplantation hospital stay (median 15 days for each) or operative mortality (3.8% vs 4.4%). Mean follow-up averaged 22 months. No significant difference was found in Kaplan-Meier survival estimates. One-year survival was 94% in the left ventricular assist device group and 88% in the control group (difference not significant). Comparison of posttransplantation events showed no significant difference in actuarial rates of cytomegalovirus infection (20% vs 17%) or vascular rejection (15% vs 12%) at 1 year of follow-up. Similar percentages of patients were free from cellular rejection at 1 year of follow-up (12% vs 22%, p= 0.36).

Conclusions: Left ventricular assist device support intensified the donor shortage by including recipients who otherwise would not have survived to transplantation. Bridging affected transplant demographics, favoring patients who are larger, have ischemic cardiomyopathy, have had multiple blood transfusions and complex cardiac operations, and are HLA sensitized. Successfully bridged patients wait longer for a transplant than do UNOS status I patients without such a bridge, but they have similar posttransplantation hospital stay, operative mortality, and survival to those of patients not requiring left ventricular assist device support. (J THORAC CARDIOVASC SURG 1996;112:1275-83)

This article has been cited by other articles:

				A. J. Clegg, D. A. Scott, E. Loveman, J. L. Colquitt, P. Royle, and J. Bryant Clinical and cost-effectiveness of left ventricular assist devices as a bridge to heart transplantation for people with end-stage heart failure: a systematic review and economic evaluation Eur. Heart J., December 2, 2006; 27(24): 2929 - 2938. [Abstract] [Full Text] [PDF]

				J. S. Gammie, L. B. Edwards, B. P. Griffith, R. N. Pierson III, and L. Tsao Optimal timing of cardiac transplantation after ventricular assist device implantation J. Thorac. Cardiovasc. Surg., June 1, 2004; 127(6): 1789 - 1799. [Abstract] [Full Text] [PDF]

				J. A. Morgan, Y. Park, A. R. Kherani, D. W. Vigilance, F. H. Cheema, M. C. Oz, and Y. Naka Does bridging to transplantation with a left ventricular assist device adversely affect posttransplantation survival? A comparative analysis of mechanical versus inotropic support J. Thorac. Cardiovasc. Surg., October 1, 2003; 126(4): 1188 - 1190. [Full Text] [PDF]

				O. Baron, A. Le Guyader, J. N. Trochu, M. Burban, J. C. Chevalier, M. Treilhaud, T. Petit, O. Al Habash, P. Despins, J. L. Michaud, et al. Does the pretransplant UNOS status modify the short- and long-term cardiac transplant prognosis? Ann. Thorac. Surg., June 1, 2003; 75(6): 1878 - 1885. [Abstract] [Full Text] [PDF]

				L. W. Miller Patient selection for the use of ventricular assist devices as a bridge to transplantation Ann. Thorac. Surg., June 1, 2003; 75(90060): S66 - 71. [Abstract] [Full Text] [PDF]

				K. D. Aaronson, M. J. Eppinger, D. B. Dyke, S. Wright, and F. D. Pagani Left ventricular assist device therapy improves utilization of donor hearts J. Am. Coll. Cardiol., April 17, 2002; 39(8): 1247 - 1254. [Abstract] [Full Text] [PDF]

				P. M. McCarthy Implantable left ventricular assist device bridge-to-transplantation: natural selection, or is this the natural selection? J. Am. Coll. Cardiol., April 17, 2002; 39(8): 1255 - 1257. [Full Text] [PDF]

				A.L. Clark, M. Loebe, E.V. Potapov, K. Egerer, C. Knosalla, R. Hetzer, and S.D. Anker Ventricular assist device in severe heart failure. Effects on cytokines, complement and body weight Eur. Heart J., December 2, 2001; 22(24): 2275 - 2283. [Abstract] [PDF]

				T. Omoto, K. Minami, T. Muramatsu, S. Kyo, and R. Korfer Pseudoaneurysm after heart transplantation with history of LVAD driveline infection Ann. Thorac. Surg., July 1, 2001; 72(1): 263 - 264. [Abstract] [Full Text] [PDF]

				S. J. Park, D. Q. Nguyen, A. J. Bank, S. Ormaza, and R. M. Bolman III Left ventricular assist device bridge therapy for acute myocardial infarction Ann. Thorac. Surg., April 1, 2000; 69(4): 1146 - 1151. [Abstract] [Full Text] [PDF]

				S. Itescu, T. C. Tung, E. M. Burke, A. Weinberg, N. Moazami, J. H. Artrip, N. Suciu-Foca, E. A. Rose, M. C. Oz, and R. E. Michler Preformed IgG Antibodies Against Major Histocompatibility Complex Class II Antigens Are Major Risk Factors for High-grade Cellular Rejection in Recipients of Heart Transplantation Circulation, August 25, 1998; 98(8): 786 - 793. [Abstract] [Full Text] [PDF]

				M. L. Dickstein Anesthesia for Heart Transplantation Seminars in Cardiothoracic and Vascular Anesthesia, July 1, 1998; 2(2): 131 - 139. [Abstract] [PDF]

				J. F. McCarthy, P. M. McCarthy, M. G. Massad, D. J. Cook, N. G. Smedira, V. Kasirajan, M. Goormastic, K. Hoercher, and J. B. Young Risk Factors for Death After Heart Transplantation: Does a Single-Center Experience Correlate With Multicenter Registries? Ann. Thorac. Surg., June 1, 1998; 65(6): 1574 - 1578. [Abstract] [Full Text] [PDF]

				J. L. Skinner, R. C. Bourge, J. K. Kirklin, D. C. McGiffin, and W. L. Holman Replacement of an Intracorporeal Left Ventricular Assist Device Ann. Thorac. Surg., September 1, 1997; 64(3): 839 - 841. [Abstract] [Full Text]